Figure 2.

Time course of DAS28 (ESR) in patients who discontinued adalimumab. The plots show individual data. A) Time course of DAS28 (ESR) at the baseline when adalimumab was initiated, at the HONOR study entry when adalimumab was withdrawn and at the primary endpoint after 24 weeks follow-up in 29 patients who maintained the DAS28 (ESR) <2.6 after discontinuation of adalimumab for at least 24 weeks. B) Time course of DAS28 (ESR) at the baseline when adalimumab was initiated, at the HONOR study entry when adalimumab was withdrawn, at the primary endpoint after 24-weeks follow-up and after methotrexate dose escalation and/or adalimumab restart in 21 patients in whom DAS28 (ESR) exceeded 2.6 within 24 weeks of adalimumab discontinuation. DAS28 (ESR), disease activity score by using 28 joints based on erythrocyte sedimentation rate; MTX, methotrexate.

Hirata et al. Arthritis Research & Therapy 2013 15:R135   doi:10.1186/ar4315
Download authors' original image